Lorenzo C.
- Country
- Italy
- Department
- Oncologia
Research Overview
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase II Evaluation of Pembrolizumab and Carboplatin in BRCA-Mutated Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 1 of 50 partner sites.
Specializations
Breast Cancer Specialization
This investigator specializes in the treatment of triple negative breast cancer (TNBC), focusing on advanced therapeutic approaches for patients with locally advanced disease stages.
- Breast Cancer Pathology
- Treatment Response Assessment
- Neoadjuvant Therapy
Their expertise extends to evaluating pathological complete response in breast cancer treatment.
Therapeutic Approaches
The investigator focuses on combining immunotherapy with conventional chemotherapy in breast cancer treatment protocols, particularly in the neoadjuvant and adjuvant settings.
- Combination Therapy Strategies
- Immunotherapy Applications
- Treatment Sequencing
Their work encompasses both pre-surgical and post-surgical therapeutic interventions.
Clinical Outcomes
The investigator's research interests include studying event-free survival and long-term treatment outcomes in breast cancer patients undergoing combined therapeutic approaches.
- Survival Analysis
- Treatment Efficacy Assessment
- Patient Monitoring
Their work contributes to understanding long-term therapeutic benefits in breast cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.